Susan Bailey, MD
Allergy · Fort Worth, TXNPI 1396722583
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 197 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. 2024 is the largest year on record at $1,842, 2.2 times the $845 reported in 2019. That places this record below the midpoint for allergy clinicians in TX, where the typical reported total is $5,140.
Across 197 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$639
- Sanofi$504
- Regeneron Healthcare Solutions, Inc.$447
- Grifols USA, LLC$439
- Blueprint Medicines Corporation$373
- Novartis$299
- plus $2K from 17 others
What the payments were for
- Food & beverage$4,39798%
- Education$802%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $639 |
| Sanofi | 19 | $504 |
| Regeneron Healthcare Solutions, Inc. | 17 | $447 |
| Grifols USA, LLC | 15 | $439 |
| Blueprint Medicines Corporation | 12 | $373 |
| Novartis | 18 | $299 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $291 |
| GSK | 14 | $249 |
| CSL Behring | 9 | $197 |
| Genentech USA, Inc. | 7 | $179 |
| Pfizer | 8 | $159 |
| Covis Pharma GmbH | 7 | $131 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Pharming Healthcare, Inc. | 3 | $78 |
| Teva Pharmaceuticals USA, Inc. | 5 | $71 |
| Amgen | 4 | $71 |
| Shire North American Group Inc | 3 | $63 |
| Optinose US, Inc. | 2 | $48 |
| Incyte Corporation | 2 | $44 |
| Alk-abello, Inc | 2 | $44 |
| Biocryst US Sales Co., LLC | 2 | $40 |
| Kaleo, Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xembify$120
How this compares
$4,477 in reported general payments places this provider in the 40th percentile of 69 allergy providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 15 | $52,928 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $34,678 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $18,455 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $12,422 |
| Arnuity ElliptaFluticasone Furoate | 35 | $10,978 |
| Pulmicort FlexhalerBudesonide | 18 | $9,238 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $8,801 |
| BreynaBudesonide/Formoterol Fumarate | 21 | $3,772 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $3,140 |
| Ipratropium Bromide | 76 | $2,054 |
| Mometasone Furoate | 14 | $1,866 |
| Azelastine Hcl | 48 | $1,717 |
| Montelukast Sodium | 179 | $1,650 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 59 | $1,402 |
| Fluticasone Propionate | 54 | $1,098 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $439 | $34,67811 claims |
| GSKBreo Ellipta, Arnuity Ellipta | $249 | $29,43360 claims |
| AstraZenecaSymbicort, Pulmicort Flexhaler | $639 | $21,66060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 69 allergy providers in Texas.
Other allergy in Fort Worth
- Dalia GaliciaFort Worth$7K
- Swapnil VaidyaFort Worth$6K
- Gary GrossDallas$602K
- Rene LeonSouthlake$48K
- Christina HuddlestonDallas$26K
- Alireza ShakouriSouthlake$17K
- Zachary MarshallRoanoke$17K
- Stuart AbramsonSan Angelo$16K
- Patricia DingerSan Antonio$15K
- Brian MillerGeorgetown$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.